Takeda has bought a licence for a coeliac disease drug from COUR Pharmaceuticals, after the US biotech announced supportive phase 2a trial data. Gastrointestinal diseases are one of the Japanese ...
If you receive JavaScript required to sign in error message when using Skype, OneDrive, Teams or any other program, you need to turn on or enable JavaScript in your ...
Hosted on MSN
Why are Coursera (COUR) shares soaring today?
Shares of online learning platform Coursera (NYSE:COUR) jumped 10.6% in the morning session after KeyBanc reiterated its Overweight rating on the stock, a positive signal for investors. The action ...
A federal appeals court ended a more than six-decade-old federal oversight of a Louisiana school system related to a desegregation mandate, a court filing showed on Tuesday, marking a win for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
CHICAGO, June 18, 2026 (GLOBE NEWSWIRE) -- COUR Pharma, a clinical-stage biotechnology company developing first-in-class, antigen-specific immune tolerance therapies for autoimmune diseases, announced ...
Studio Pierrot has unveiled the first teaser trailer and key visual for the final part of the Bleach anime, Thousand-Year Blood War (TYBW) Cour 4, confirming its release in July 2026. This last ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
This library serves as a comprehensive reference implementation of MessagePack for JavaScript with a focus on accuracy, compatibility, interoperability, and performance. Additionally, this is also a ...
US biotech COUR Pharma has closed a $50 million series B financing round to advance CNP-103, its experimental type 1 diabetes therapy designed to address the autoimmune cause of the disease rather ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results